TOP TIERMARKET NEWSWIRE

News & sentiment

AIM IMMUNOTECH INC (AIM) — News & AI sentiment

AIM IMMUNOTECH INC (AIM) news roundup. 4 stories in the past week, 11 over 30 days. Average 30-day sentiment is 59.3/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

4

avg sentiment 57.3/100

30d stories

11

avg sentiment 59.3/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

AIM news in the last 24 hours, 7 days, 30 days and 90 days

How much AIM coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	AIM stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	4	57.3/100	AIM headlines →
Last 30 days	11	59.3/100	AIM headlines →
Last 90 days	28	55.9/100	AIM headlines →

Latest stories on AIM

AIM ImmunoTech Reduces Debt via Equity Exchange Agreements

TipRanks53 · neutralgeneral

3d ago

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

3d ago

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

StockTitan63 · neutralproduct/pr

4d ago

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

GlobeNewswire63 · neutralproduct/pr

4d ago

AIM ImmunoTech Extinguishes Debt Through Equity Exchanges

TipRanks58 · neutralgeneral

Sep 4

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

Sep 4

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

StockTitan63 · neutralproduct/pr

Sep 2

AIM ImmunoTech granted patent for Ampligen

The Fly63 · neutralproduct/pr

Aug 31

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

StockTitan67 · bullishproduct/pr

Aug 31

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

GlobeNewswire67 · bullishproduct/pr

Aug 31

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

GlobeNewswire55 · neutralgeneral

Aug 27

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article

StockTitan58 · neutralproduct/pr

Aug 12

AIM ImmunoTech CEO Urges Biodefense Military Integration

TipRanks58 · neutralgeneral

Aug 11

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

Aug 11

AIM ImmunoTech GAAP EPS of -$0.43

Seeking Alpha34 · bearishearnings

Aug 10

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

Aug 10

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer

StockTitan63 · neutralearnings

Aug 10

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

Aug 6

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

Aug 5

AIM ImmunoTech Stockholders Approve Key Equity Proposals

TipRanks50 · neutralgeneral

Jul 17

AIM ImmunoTech Inc. (AIM) files 8-K

SEC 8-K50 · neutralgeneral

Jul 16

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program | AIM Stock News

StockTitan67 · bullishproduct/pr

Jul 7

Silver Bullet shifts year end as AIM trading faces suspension

TipRanks32 · bearishgeneral

Jun 29

Gana Media Director Increases Stake with AIM Share Purchase

TipRanks56 · neutralgeneral

Jun 24

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones | AIM Stock News

StockTitan63 · neutralproduct/pr

Jun 24

Open AIM in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →